volixibat

News

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

News

GSK reveals the data behind its linerixibat for itching associated with autoimmune liver disease PBC as it anticipates first approvals for the drug.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.